

CITATION REPORT

List of articles citing

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

DOI: 10.2165/00003088-200544100-00001
Clinical Pharmacokinetics, 2005, 44, 989-1008.

Source: <https://exaly.com/paper-pdf/39421318/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
501	Gaps in knowledge in treating pregnant women. 2006 , 3, 169-82		43
500	A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. 2006 , 62, 552-9		33
499	Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. 2006 , 2, 947-60		60
498	Transplacental passage of vancomycin in noninfected term pregnant women. 2007 , 109, 1105-10		26
497	Alterations in drug disposition during pregnancy. 2007 , 3, 557-571		81
496	Gestational age dependency in the prenatal toxicity and in the disposition kinetics of the novel anticonvulsant HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) after subcutaneous administration in pregnant rats. 2007 , 26, 237-46		2
495	Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. 2007 , 50, 123-31		18
494	The fate and effects of xenobiotics in human placenta. 2007 , 3, 331-46		76
493	The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy. 2007 , 16, 807-17		15
492	Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 209-19	6.2	81
491	Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. 2007 , 22, 100-6		9
490	Obstetric clinical pharmacology: coming of age. 2007 , 81, 481-2		25
489	Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. 2007 , 64, 634-44		20
488	Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. 2007 , 48, 1111-6		146
487	Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. 2007 , 73, 1012-9		29
486	Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus. 2007 , 21, 159-63		13
485	Ritodrine pharmacokinetics in twin pregnancy patients. 2008 , 64, 399-404		4

484	Biological rhythms: a neglected factor of variability in pharmacokinetic studies. 2008 , 97, 1099-108	19
483	Embryotoxicity of artesunate in animal species related to drug tissue distribution and toxicokinetic profiles. 2008 , 83, 435-45	16
482	Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. 2008 , 84, 662-73	59
481	Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. 2008 , 84, 248-53	173
480	Steady-state nevirapine plasma concentrations are influenced by pregnancy. 2008 , 9, 234-8	8
479	Where do we go now with low molecular weight heparin use in obstetric care?. 2008 , 6, 1461-7	19
478	Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. 2008 , 66, 179-95	52
477	The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. 2008 , 66, 866-74	20
476	Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. 2008 , 75, 1677-87	25
475	Principles of Drug Dosing in Critically Ill Patients. 2008 , 343-376	5
474	Sex-specific differences in CYP450 isoforms in humans. 2008 , 4, 413-24	121
473	Obstetric anesthesia: outside the labor and delivery unit. 2008 , 26, 89-108, vii	
472	Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. 2008 , 17, 160-5	39
471	Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. 2008 , 17, 192-8	62
470	Neuroanesthesia for the pregnant woman. 2008 , 107, 193-200	89
469	Pharmacokinetics of antiepileptic drugs in pregnancy. 2008 , 1, 129-36	4
468	Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. 2008 , 2008, 5454-7	16
467	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. 2008 , 38, 62-75	81

466	Decrease in protein binding and its effect on toxicokinetics (TK)/toxicodynamics (TD) of diclofenac and propranolol in pregnant rats. 2008 , 33, 525-36	3
465	Toxicokinetic and toxicodynamic analysis of clofibrate based on free drug concentrations in nage analbuminemia rats (NAR). 2008 , 33, 349-61	9
464	Pharmacological aspects of neonatal antidepressant withdrawal. 2008 , 63, 267-79	30
463	Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens. 2008 , 30, 604-10	7
462	Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. 2008 , 30, 173-80	51
461	Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. 2008 , 30, 511-22	40
460	Glomerular hyperfiltration and albuminuria in critically ill patients. 2008 , 36, 674-80	70
459	A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV. 2009 , 8, 683-94	9
458	Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. 2009 , 53, 4368-76	49
457	Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. 2009 , 37, 1841-7	101
456	Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. 2009 , 55, 1177-87	29
455	Sex differences in the expression of hepatic drug metabolizing enzymes. 2009 , 76, 215-28	497
454	As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate <i>Macaca nemestrina</i> . 2009 , 329, 1016-22	2
453	Therapeutic product disposition in at-risk populations. 2009 , 134, 184-90	2
452	Optimizing pediatric dosing: a developmental pharmacologic approach. 2009 , 29, 680-90	92
451	Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. 2009 , 98, 2317-35	23
450	Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. 2009 , 98, 2832-46	26
449	Effect of pregnancy on nitrofurantoin disposition in mice. 2009 , 98, 4306-15	4

448	Serum concentration/dose ratio of topiramate during pregnancy. 2009 , 50, 480-5		38
447	Seizure deterioration in women treated with oxcarbazepine during pregnancy. 2009 , 84, 245-9		37
446	Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. 2009 , 200, 170.e1-7		34
445	Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. 2009 , 30, 613-69		51
444	Bisphenol A levels in blood depend on age and exposure. 2009 , 190, 32-40		104
443	Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 159-68	6.2	33
442	Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 677-83	6.2	66
441	Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-adrenal axis function in humans: a systematic review. 2009 , 30, 753-89		90
440	Novel biomarkers of prenatal methamphetamine exposure in human meconium. 2009 , 31, 70-5		16
439	Sex Differences of Drug-metabolizing Enzyme: Female Predominant Expression of Human and Mouse Cytochrome P450 3A Isoforms. 2009 , 55, 325-337		28
438	Hypoglycemics: pharmacokinetic considerations during pregnancy. 2009 , 31, 533-41		6
437	Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. 2010 , 30, 381-6		20
436	High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. 2010 , 24, 2416-8		35
435	Pregnancy and commonly used drugs in hematology practice. 2010 , 2010, 160-5		7
434	Scientific Opinion on Bisphenol A: evaluation of a study investigating its neurodevelopmental toxicity, review of recent scientific literature on its toxicity and advice on the Danish risk assessment of Bisphenol A. 2010 , 8, 1829		71
433	Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. 2010 , 203, 254.e1-12		25
432	Improved recipient survival with maternal nifedipine in twin-twin transfusion syndrome complicated by TTTS cardiomyopathy undergoing selective fetoscopic laser photocoagulation. 2010 , 203, 397.e1-9		13
431	Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. 2010 , 196, 93-6		14

430	Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. 2010 , 7, 18	6
429	Gene profiling of maternal hepatic adaptations to pregnancy. 2010 , 30, 406-15	30
428	Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. 2010 , 87, 226-34	42
427	Management of pregnant female with meningioma for craniotomy. 2010 , 1, 35-7	9
426	Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. 2010 , 15, 127-9	11
425	Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. 2010 , 44, 1342-4	24
424	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. 2010 , 38, 1393-6	48
423	State of the art in therapeutic drug monitoring. 2010 , 48, 437-46	11
422	Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. 2010 , 6, 689-99	98
421	Pharmacokinetic properties of azithromycin in pregnancy. 2010 , 54, 360-6	37
420	Breast cancer and pregnancy: current concepts in diagnosis and treatment. 2010 , 15, 1238-47	33
419	Passage transplacentaire des antirétroviraux. 2010 , 12, 228-234	
418	Taxanes for breast cancer during pregnancy: a systematic review. 2010 , 21, 425-426	110
417	Drug development for use during pregnancy: impact of the placenta. 2010 , 5, 437-454	12
416	Effect of pregnancy on topiramate pharmacokinetics in rabbits. 2011 , 41, 416-21	3
415	Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. 2011 , 15, 253-61	6
414	Pharmacokinetic Behaviors of Orally Administered Drugs. 2011 , 183-219	2
413	Systematic review of pregnancy in women with inherited cardiomyopathies. 2011 , 13, 584-94	57

412	Screening for drugs of abuse: which matrix, oral fluid or urine?. 2011 , 48, 531-41	50
411	Pharmacokinetic variation. 2011 , 12, 368-370	2
410	Nutrition and human health from a sex-gender perspective. 2011 , 32, 1-70	88
409	Quantitative shot-gun proteomics and MS-based activity assay for revealing gender differences in enzyme contents for rat liver microsome. 2011 , 74, 2734-44	22
408	ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). 2011 , 32, 3147-97	1167
407	Obstetric pharmacology. 948-962	
406	Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza. 2011 , 118, 463-467	9
405	Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. 2011 , 25, 1299-303	19
404	A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. 2011 , 26, 2283-8	20
403	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. 2011 , 2, 1437-53	22
402	Prophylaxis with low-dose low molecular weight heparin during pregnancy and the puerperium: is it effective? A rebuttal. 2011 , 9, 1269-71; author reply 1272-3	4
401	Oseltamivir pharmacokinetics in pregnancy: a commentary. 2011 , 204, S94-5	7
400	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. 2011 , 204, S84-8	60
399	Isoform-specific regulation of cytochrome P450 expression and activity by estradiol in female rats. 2011 , 81, 777-82	20
398	Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more. 2011 , 20, 1-6	45
397	Implications of augmented renal clearance in critically ill patients. 2011 , 7, 539-43	120
396	Physiologically-Based Pharmacokinetics. 2011 , 361-386	
395	Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4-hydroxycholesterol. 2011 , 67, 715-22	15

394	Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. 2011 , 67, 899-908	27
393	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. 2011 , 10, 114	39
392	Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. 2011 , 94, 198-205	30
391	Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. 2011 , 41, 263-91	244
390	Altered cytochrome P450 expression in mice during pregnancy. 2011 , 39, 165-9	36
389	Pregnancy-associated breast cancer. 2011 , 54, 546-55	11
388	Pharmacokinetics in pregnancy. 2011 , 39-45	3
387	Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. 2011 , 16, 56-67	40
386	Pregnancy decreases rat CYP1A2 activity and expression. 2011 , 39, 4-7	7
385	Maternal hepatic growth response to pregnancy in the mouse. 2011 , 236, 1322-32	24
384	Clinical therapeutics in pregnancy. 2011 , 2011, 783528	38
383	Repression of hepatobiliary transporters and differential regulation of classic and alternative bile acid pathways in mice during pregnancy. 2012 , 130, 257-68	24
382	Influenza during pregnancy: a cause of serious infection in obstetrics. 2012 , 55, 914-26	12
381	Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. 2012 , 55, 1532-49	155
380	Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. 2012 , 56, 776-82	24
379	Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. 2012 , 56, 715-24	14
378	Disposition of drugs in pregnancy: anti-epileptic drugs. 2012 , 27-33	
377	The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. 2012 , 2012, 437639	7

376	Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. 2012 , 56, 857-62	37
375	Taxanes during pregnancy: probably safe, but still to be optimized. 2012 , 83, 239-40	16
374	Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. 2012 , 56, 5764-73	35
373	Population pharmacokinetics of dihydroartemisinin and piperazine in pregnant and nonpregnant women with uncomplicated malaria. 2012 , 56, 1997-2007	80
372	Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. 2013 , 18, 171-82	25
371	Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors. 2012 , 57, 523-9	12
370	A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. 2012 , 1, e3	61
369	Prescribing without evidence - pregnancy. 2012 , 74, 691-7	31
368	Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs. 2012 , 1-29	8
367	Urinary ochratoxin A and ochratoxin alpha in pregnant women. 2012 , 50, 4487-92	35
366	Physiologic adaptations to pregnancy. 2012 , 30, 781-9	59
365	Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 2012 , 44, 381-7	12
364	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. 2012 , 13, 1501-22	22
363	Guía de práctica clínica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. 2012 , 65, 171.e1-171.e44	6
362	Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier. 2012 , 8, 1263-75	31
361	Pharmacokinetics and Pharmacodynamics: The Role of Sex and Gender. 2012 , 183-194	3
360	Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. 2012 , 21, 125-8	14
359	An Introduction to Tests Performed in Toxicology Laboratories. 2012 , 1-30	

358	The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. 2012 , 74, 932-9	21
357	A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. 2012 , 74, 873-85	80
356	Anticoagulation during pregnancy in patients with a prosthetic heart valve. 2012 , 9, 415-24	33
355	Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 365-96	6.2 210
354	Increased evidence for use of chemotherapy in pregnancy. 2012 , 13, 852-4	11
353	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. 2012 , 207, 514.e1-7	23
352	Biotransformation of 2,3,3,3-tetrafluoropropene (HFO-1234yf) in male, pregnant and non-pregnant female rabbits after single high dose inhalation exposure. 2012 , 263, 32-8	6
351	Maternal and preterm fetal sheep responses to dexmedetomidine. 2012 , 21, 339-47	15
350	A population pharmacokinetic model of piperazine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. 2012 , 11, 398	36
349	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. 2012 , 11, 293	36
348	Drug Interactions at the Human Placenta: What is the Evidence?. 2012 , 3, 126	39
347	Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. 2012 , 12, 707-17	34
346	A Practitioner's Guide to Prescribing Phenobarbital for Adults with Intellectual Disabilities. 2012 , 279-301	
345	Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women. 2012 , 29, 1609-17	10
344	Differences in metabolite burden of di(2-ethylhexyl)phthalate in pregnant and postpartum dams and their offspring in relation to drug-metabolizing enzymes in mice. 2012 , 86, 563-9	12
343	Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. 2012 , 73, 248-56	10
342	Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy. 2012 , 84, 93-103	48
341	Prescribing medicines in pregnancy. 2012 , 40, 386-390	

340	Effect of blood protein concentrations on drug-dosing regimes: practical guidance. 2013 , 10, 20	10
339	Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. 2013 , 39, 977-8	13
338	Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. 2013 , 225, 441-51	28
337	A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. 2013 , 15, 1012-24	45
336	Pharmacokinetics of puerarin in pregnant rats at different stages of gestation after oral administration. 2013 , 86, 202-7	14
335	Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. 2013 , 75, 850-60	37
334	Renal transporters in drug development. 2013 , 53, 503-29	226
333	Stereoselective determination of metoprolol and its metabolite β -hydroxymetoprolol in plasma by LC-MS/MS: application to pharmacokinetics during pregnancy. 2013 , 25, 1-7	10
332	Urinary analysis reveals high deoxynivalenol exposure in pregnant women from Croatia. 2013 , 62, 231-7	60
331	Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. 2013 , 54, 405-14	171
330	Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. 2013 , 53, 119-39	45
329	Pharmacokinetic variation. 2013 , 14, 126-128	2
328	The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. 2013 , 27, 739-48	59
327	Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. 2013 , 57, 5096-103	37
326	Pregnancy and pharmacogenomics in the context of drug metabolism and response. 2013 , 14, 1779-91	8
325	Impact of pregnancy on zonisamide pharmacokinetics in rabbits. 2013 , 2013, 140327	1
324	Pharmacology and pharmacogenomics of neurological medications used in pregnancy. 2013 , 56, 305-16	4
323	Therapeutic drug monitoring of antiepileptic drugs by use of saliva. 2013 , 35, 4-29	126

322	Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?. 2013 , 41, 256-62	126
321	Regulation of hepatic phase II metabolism in pregnant mice. 2013 , 344, 244-52	20
320	Population pharmacokinetics of enoxaparin during the antenatal period. 2013 , 128, 1462-9	32
319	Ochratoxin A levels in blood serum of Czech women in the first trimester of pregnancy and its correspondence with dietary intake of the mycotoxin contaminant. 2013 , 18, 673-8	19
318	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. 2013 , 41, 263-9	102
317	Alteration of the expression of pesticide-metabolizing enzymes in pregnant mice: potential role in the increased vulnerability of the developing brain. 2013 , 41, 326-31	17
316	A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. 2013 , 41, 801-13	72
315	Hormonal regulation of hepatic drug biotransformation and transport systems. 2013 , 3, 1721-40	8
314	Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy. 2013 , 41, 312-9	13
313	Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. 2013 , 41, 332-42	41
312	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. 2013 , 8, 871-890	8
311	Explaining human recreational use of 'pesticides': The neurotoxin regulation model of substance use vs. the hijack model and implications for age and sex differences in drug consumption. 2013 , 4, 142	36
310	The role of clomipramine in potentiating the teratogenic effects of caffeine in pregnant rats: a histopathological study. 2013 , 2013, 382434	4
309	Physiologic and pharmacokinetic changes in pregnancy. 2014 , 5, 65	201
308	Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age. 2014 , 350, 425-34	12
307	Predictors of blood trihalomethane concentrations in NHANES 1999-2006. 2014 , 122, 695-702	26
306	Sex and gender influences on pharmacological response: an overview. 2014 , 7, 469-85	70
305	Grossesse et médicaments. 2014 , 425-433	

304	Semiphiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. 2014 , 2014, 897216	15
303	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. 2014 , 77, 554-70	74
302	Therapeutic Drug Monitoring. 2014 , 249-273	
301	Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. 2014 , 15, 50-6	42
300	Is personalized medicine achievable in obstetrics?. 2014 , 38, 534-40	7
299	A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?. 2014 , 134, 1234-40	31
298	Prevention and management of influenza in pregnancy. 2014 , 41, 535-46	14
297	Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. 2014 , 54, 432-7	13
296	Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. 2014 , 58, 2256-61	32
295	Pregnancy complicated by valvular heart disease: an update. 2014 , 3, e000712	55
294	Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. 2014 , 34, 244-55	130
293	Do lopinavir and ritonavir require a dose adjustment during pregnancy?. 2014 , 66, e64-5	1
292	Estradiol and weight are covariates of paracetamol clearance in young women. 2014 , 77, 211-6	4
291	Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. 2014 , 78, 1378-86	9
290	Toxicokinetic aspects of thiocyanate after oral exposure to cyanide in female Wistar rats in different physiological states. 2014 , 37, 63-8	4
289	Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. 2014 , 171, 580-94	127
288	Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 373-83	6.2 36
287	Management of cardiovascular diseases during pregnancy. 2014 , 39, 85-151	21

286	Pharmacometrics in pregnancy: An unmet need. 2014 , 54, 53-69	62
285	ADHD treatment and pregnancy. 2014 , 37, 397-408	14
284	Oseltamivir for influenza in pregnancy. 2014 , 38, 503-7	5
283	Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. 2014 , 25, 2059-2065	46
282	Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: a preclinical investigation. 2014 , 65, 38-44	2
281	Microphysiological modeling of the reproductive tract: a fertile endeavor. 2014 , 239, 1192-202	25
280	Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. 2014 , 39, 541-4	6
279	Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats. 2014 , 73, 1041-5	8
278	Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges. 2014 , 17, 239-46	5
277	A review of physiological and behavioral changes during pregnancy and lactation: potential exposure factors and data gaps. 2014 , 24, 449-58	56
276	Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. 2014 , 58, 4583-92	34
275	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. 2014 , 69, 3033-40	17
274	Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. 2014 , 144, 134-61	66
273	[Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring]. 2014 , 69, 223-34	5
272	Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. 2015 , 80, 642-53	24
271	Oseltamivir for the treatment of H1N1 influenza during pregnancy. 2015 , 98, 403-5	4
270	Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. 2015 , 97, 298-306	36
269	Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring. 2015 , 37, 285-7	4

268	Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. 2015 , 80, 1031-41	45
267	Possible Rivaroxaban Failure during the Postpartum Period. 2015 , 35, e164-8	11
266	Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach. 2015 , 37, 334-42	12
265	Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. 2015 , 59, 4260-71	25
264	Antipsychotic use in pregnancy. 2015 , 16, 1335-45	31
263	A Review of Antibiotic Use in Pregnancy. 2015 , 35, 1052-62	135
262	Changes in the rate of nicotine metabolism across pregnancy: a longitudinal study. 2015 , 110, 1827-32	48
261	CYP3A activity based on plasma 4βhydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. 2015 , 30, 419-24	10
260	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. 2015 , 47, 470-519	46
259	Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. 2015 , 97, 167-76	17
258	Acute myeloid leukemia in the pregnant patient. 2015 , 95, 124-36	12
257	Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients. 2015 , 79, 605-16	10
256	Plasma levels of oral risperidone during enteral nutrition in a pregnant schizophrenic patient. 2015 , 5, 133-7	0
255	Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. 2015 , 993-994, 20-5	4
254	EPMA position paper in cancer: current overview and future perspectives. 2015 , 6, 9	60
253	Maternal Adaptations to Pregnancy. 2015 , 1927-1955	2
252	Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. 2015 , 61, 809-16	46
251	Epidemiology of medications use in pregnancy. 2015 , 39, 508-11	52

250	Pharmacokinetics of drugs in pregnancy. 2015 , 39, 512-9	153
249	Pharmacokinetics of clomipramine during pregnancy. 2015 , 71, 1493-500	4
248	The importance of studying antimicrobials in pregnancy. 2015 , 39, 556-60	4
247	Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. 2015 , 61, 1582-9	12
246	Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. 2015 , 132, 1747-73	198
245	Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. 2015 , 59, 6375-84	19
244	Therapeutic drug monitoring in HIV-infected pregnant women with a focus on protease inhibitors. 2015 , 10, 915-922	
243	Pharmacologic studies in vulnerable populations: Using the pediatric experience. 2015 , 39, 532-6	13
242	Use of medication for cardiovascular disease during pregnancy. 2015 , 12, 718-29	37
241	Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. 2015 , 16, 176-83	12
240	Need for gender-specific pre-analytical testing: the dark side of the moon in laboratory testing. 2015 , 179, 514-35	19
239	Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. 2015 , 70, 534-42	29
238	Blood Biomarkers of Late Pregnancy Exposure to Trihalomethanes in Drinking Water and Fetal Growth Measures and Gestational Age in a Chinese Cohort. 2016 , 124, 536-41	46
237	Therapeutic Drug Monitoring in Pregnancy. 2016 , 185-211	1
236	Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. 2016 , 7, 239	12
235	Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Pregnancy and Parturition. 2016 , 122, 786-804	42
234	Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. 2016 , 73, 268-274	9
233	Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. 2016 , 26, 381-9	8

232	Population pharmacokinetics of 17 β -hydroxyprogesterone caproate in singleton gestation. 2016 , 82, 1084-93	7
231	Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression. 2016 , 100, 31-3	9
230	Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. 2016 , 56, 590-6	33
229	Pharmacogenomics of preterm birth prevention and treatment. 2016 , 123, 368-75	16
228	Pharmacokinetic variation. 2016 , 17, 163-165	3
227	Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. 2016 , 215, S1-S46	147
226	Issues for Women with Epilepsy. 2016 , 34, 411-25, ix	15
225	Use of anticancer agents in gynecological oncology during pregnancy: a systematic review of maternal pharmacokinetics and transplacental transfer. 2016 , 12, 523-31	7
224	Drug therapy during pregnancy: implications for dental practice. 2016 , 220, 413-7	10
223	Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant. 2016 , 36, 971-82	9
222	Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. 2016 , 44, 1832-1838	14
221	Anticoagulation During Pregnancy: Evolving Strategies With a Focus on Mechanical Valves. 2016 , 68, 1804-1813	49
220	Rifapentine for the treatment of latent tuberculosis. 2016 , 9, 1253-1261	1
219	Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. 2016 , 116, 687-95	8
218	Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. 2015 , 60, 1274-82	24
217	Treatment regimens for pregnant women with falciparum malaria. 2016 , 14, 691-704	7
216	Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template. 2016 , 25, 761-6	7
215	Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy. 2016 , 7, 327-38	12

214	Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. 2015 , 60, 1234-41	22
213	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. 2016 , 62, 761-769	32
212	No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects. 2016 , 60, 400-8	6
211	Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 381-96	6.2 35
210	A pharmacological approach to panic disorder during pregnancy. 2016 , 29, 1468-75	1
209	Alternative Sampling Strategies for Cytochrome P450 Phenotyping. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 169-84	6.2 8
208	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs. 2017 , 45, 939-946	51
207	How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. 2017 , 18, 351-362	31
206	Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. 2017 , 61,	4
205	Thiocyanate: a review and evaluation of the kinetics and the modes of action for thyroid hormone perturbations. 2017 , 47, 537-563	19
204	Sex Differences: A Resultant of an Evolutionary Pressure?. 2017 , 25, 499-505	37
203	Treatment of infections during pregnancy: Progress and challenges. 2017 , 109, 387-390	1
202	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. 2017 , 83, 1966-1975	7
201	Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. 2017 , 38, 426-438	23
200	Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. 2017 , 106, 2380-2391	39
199	Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma. 2017 , 125, 223-231	32
198	Prediction of sustained fetal toxicity induced by ketoprofen based on PK/PD analysis using human placental perfusion and rat toxicity data. 2017 , 83, 2503-2516	3
197	Feasibility of the Von Willebrand disease PREVENT trial. 2017 , 156, 8-13	9

196	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. 2017 , 45, 920-938	55
195	Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study. 2017 , 83, 2283-2291	4
194	Optimal administration of cefazolin prophylaxis for cesarean delivery. 2017 , 37, 16-20	4
193	Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. 2017 , 83, 1571-1579	12
192	Placental Nano-vesicles Target to Specific Organs and Modulate Vascular Tone In Vivo. 2017 , 32, 2188-2198	30
191	Free drug concentrations in pregnancy: Bound to measure unbound?. 2017 , 83, 2595-2598	16
190	Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. 2017 , 50, 542-551	12
189	Pharmacokinetics in Pregnancy. 2017 , 39-49	
188	Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole. 2017 , 106, 560-569	31
187	Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. 2017 , 216, 64.e1-64.e7	31
186	Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease. 2017 , 1, 703-706	10
185	Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. 2017 , 12, e0181082	18
184	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. 2017 , 16, 267	22
183	Association between Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy. 2017 , 8, 402	16
182	Cytotoxicity, genotoxicity, transplacental transfer and tissue disposition in pregnant rats mediated by nanoparticles: the case of magnetic core mesoporous silica nanoparticles. 2018 , 46, 527-538	20
181	Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. 2018 , 7, 147-159	10
180	Prevalence and determinants of vitamin D deficiency in the third trimester of pregnancy: a multicentre study in Switzerland. 2018 , 119, 299-309	25
179	Cardiac arrest during pregnancy: ongoing clinical conundrum. 2018 , 219, 52-61	38

178	Translational Systems Pharmacology Studies in Pregnant Women. 2018 , 7, 69-81		4
177	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. 2018 , 130, 74-84		8
176	Guide for Drug Selection During Pregnancy and Lactation: What Pharmacists Need to Know for Current Practice. 2018 , 52, 810-818		8
175	Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition. 2018 , 103, 477-484		37
174	A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 749-768	6.2	33
173	17Estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes. 2018 , 819, 98-107		5
172	Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation. 2018 , 46, 100-108		7
171	Drugs and medication in pregnancy. 2018 , 233-243		
170	Neurologic disease. 2018 , 315-324		
169	OBSOLETE: Management of Pregnancy With Underlying Congenital and Acquired Cardiac Disease. 2018 ,		
168	Hematological malignancies during pregnancy. 2019 , 10, 3-9		3
167	Active Oxygen Defenses. 2018 , 195-222		
166	Acute Respiratory Distress Syndrome in Pregnancy. 2018 , 403-417		1
165	Venous thromboembolism and women's health. 2018 , 183, 346-363		16
164	Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. 2018 , 40, 526-548		167
163	Management of Pregnancy With Underlying Congenital and Acquired Cardiac Disease. 2018 , 282-291		
162	Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. 2018 , 315, L276-L285		16
161	Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. 2018 , 62,		10

160	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. 2018 , 39, 3165-3241	735
159	Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report. 2019 , 12, 5679-5685	1
158	Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. 2019 , 16, e1002842	19
157	Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. 2019 , 60, 566	
156	Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies. 2019 , 27-43	3
155	Cardiopulmonary Resuscitation of Pregnant Women. 2019 , 397-418	
154	Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. 2019 , 381, 1333-1346	52
153	Use of Antipsychotic Drugs During Pregnancy. 2019 , 6, 17-31	3
152	Physiologically-based pharmacokinetics of ziprasidone in pregnant women. 2019 , 85, 914-923	10
151	A pharmacokinetic assessment of optimal dosing, preparation, and chronotheapy of aspirin in pregnancy. 2019 , 221, 255.e1-255.e9	16
150	Quantifying Hepatic Enzyme Kinetics of (-)- Δ^9 -Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. 2019 , 47, 743-752	7
149	Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen. 2019 , 20, 337-343	12
148	Clinical Pharmacology and Pharmacometrics to Better Understand Physiological Changes During Pregnancy and Neonatal Life. 2020 , 261, 325-337	6
147	Chinese herbal medicine for acute upper respiratory tract infections and reproductive safety: A systematic review. 2019 , 13, 117-129	8
146	Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. 2019 , 69, 1254-1258	27
145	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. 2019 , 74, 1348-1356	5
144	Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. 2019 , 24, 229-233	2
143	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. 2019 , 20, 217-223	1

142	Pregnancy and Genotype Affect Day 7 Plasma Lumefantrine Concentrations. 2019 , 47, 1415-1424	8
141	Cardiovascular Drugs in Pregnancy and Lactation. 2019 , 456-490	
140	Diagnosis and Treatment of Breast Cancer in Young Women. 2019 , 20, 86	25
139	Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint. 2019 , 33, 1089-1093	16
138	Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. 2019 , 44, 83-89	3
137	Hepatic Enzymes Relevant to the Disposition of (-)- Δ^9 -Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. 2019 , 47, 249-256	12
136	Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. 2019 , 164, 268-275	10
135	Anesthetic Considerations for the Gravid Patient for Non-obstetric Surgery. 2019 , 99-108	0
134	Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. 2019 , 105, 1003-1008	1
133	Pharmacokinetics and Pharmacodynamics. 2020 , 581-587.e1	
132	Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 427-445	6.2 14
131	Therapeutic Drug Monitoring in Pregnant Patients. 2020 , 42, 172-180	2
130	Nonprescription drugs recommended in guidelines for common pain conditions. 2020 , 10, 117-129	7
129	Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. 2020 , 29, 310-318	12
128	Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. 2020 , 64,	2
127	Trimester-Specific Blood Trihalomethane and Urinary Haloacetic Acid Concentrations and Adverse Birth Outcomes: Identifying Windows of Vulnerability during Pregnancy. 2020 , 128, 107001	10
126	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. 2020 , 52, 1551-1562	14
125	Changes in physiology and immune system during pregnancy and coronavirus infection: A review. 2020 , 255, 124-128	7

124	Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics. 2020 , 48, 735-741		23
123	Model-Informed Dose Optimization in Pregnancy. 2020 , 60 Suppl 1, S63-S76		4
122	Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV. 2020 , 42, 1818-1825		0
121	Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1217-1236	6.2	3
120	Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and Its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review. 2020 , 42, 518-531		12
119	Isoniazid preventive therapy in HIV-infected pregnant and postpartum women in high prevalence of tuberculosis countries: A protocol for systematic review. 2020 , 99, e23089		
118	The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling. 2020 , 60 Suppl 2, S18-S25		1
117	Citalopram in Treatment of Pregnant Women With Panic Disorder: A Retrospective Study. 2020 , 40, 615-617		
116	Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. 2020 , 6, 36		5
115	A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa. 2020 , 64,		11
114	Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review. 2020 , 42, 229-244		5
113	Respiratory Drug Therapy in Pregnancy. 2020 , 195-199		
112	Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure. 2020 , 76, 969-977		3
111	Effects of Pregnancy on the Pharmacokinetics of Metformin. 2020 , 48, 264-271		15
110	Methods to study mechanisms underlying altered hepatic drug elimination during pregnancy. 2020 , 44, 151228		2
109	Exposure to per- and polyfluorinated alkyl substances in pregnant Brazilian women and its association with fetal growth. 2020 , 187, 109585		11
108	Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. 2020 , 64,		2
107	Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. 2020 , 47, 319-340		16

106	The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. 2021 , 72, 121-127	7
105	Drugs in pregnancy: Pharmacologic and physiologic changes that affect clinical care. 2020 , 44, 151221	7
104	Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor. 2020 , 37, 44	3
103	Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. 2020 , 112, 104569	0
102	Pharmacogenomics in pregnancy. 2020 , 44, 151222	5
101	Anatomical and physiological alterations of pregnancy. 2020 , 47, 271-285	18
100	Pharmacokinetics of HIV therapies in pregnant patients: an update. 2020 , 16, 449-461	1
99	Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. 2020 , 64,	11
98	Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of Antiretroviral agents in HIV-infected pregnant women (PANNA) Network. 2020 , 71, e714-e717	4
97	Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. 2021 , 61, 388-393	1
96	Changes in erythrocyte membrane epoxyeicosatrienoic, dihydroxyeicosatrienoic, and hydroxyeicosatetraenoic acids during pregnancy. 2021 , 264, 118590	1
95	Molecular mechanisms of developmental toxicities of azoxystrobin and pyraclostrobin toward zebrafish (<i>Danio rerio</i>) embryos: Visualization of abnormal development using two transgenic lines. 2021 , 270, 116087	2
94	A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV. 2021 , 10, 161-172	1
93	Kinetics of maternal-fetal drug transfer. 2021 , 145-162	
92	Therapeutic drug monitoring. 2021 , 295-323	
91	Implications for sex-related issues in clinical pharmacology and biopharmaceutics. 2021 , 465-485	
90	Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents. 2021 , 13,	5
89	Key hepatic metabolic pathways are altered in germ-free mice during pregnancy. 2021 , 16, e0248351	2

88	When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations. 2021 , 42, 160-177	1
87	Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. 2021 , 12, 655320	3
86	Antibiotic use amongst pregnant women in a public hospital in KwaZulu-Natal. 2021 , 26, 1516	0
85	Development and Verification of a Linked -THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. 2021 , 49, 509-520	4
84	Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. 2021 , 110, 926-940	3
83	A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment. 2021 , 12, 622948	2
82	Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. 2021 , 169, 105610	3
81	Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. 2021 ,	3
80	Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy. 2021 , 46, 1459-1464	0
79	Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. 2021 ,	2
78	Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters. 2021 , 49, 929-937	3
77	Maternal Exposure and Neonatal Effects of Drugs of Abuse. 2021 , 61 Suppl 2, S142-S155	0
76	Determination of hand grip strength and its correlates during pregnancy: a cross-sectional study. 2021 , 21, 540	
75	Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation. 2021 , 49, 919-928	4
74	Pharmacology Considerations in Women in Lung Disease and Critical Care. 2021 , 42, 557-566	0
73	MATERNAL AND FETAL BUPRENORPHINE PHARMACOKINETICS IN PREGNANT SHEEP DURING TRANSDERMAL PATCH DOSING: Buprenorphine pharmacokinetics in pregnant sheep. 2021 , 165, 105936	0
72	Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States. 2021 , 110, 3331-3344	6
71	Unique Features of Cardiovascular Pharmacology in Pregnancy and Lactation. 2021 , 437-478	

70	Sources of Interindividual Variability. 2021 , 2342, 481-550	1
69	Nonlinear Mixed Effects Models: Practical Issues. 2011 , 303-358	2
68	Diagnosis and Treatment of Depression During Pregnancy and Lactation. 2011 , 309-354	1
67	Sources of interindividual variability. 2014 , 1113, 363-415	20
66	Anticoagulants and Antiplatelet Agents in Pregnancy. 2015 , 15-39	2
65	Non-front-Fanged Colubroid (Bear-Fanged) Snakes. 2016 , 1-41	1
64	Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. 2011 , 33, 619-26	35
63	Medicines in pregnancy. 2019 , 8,	14
62	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated malaria in Burkina Faso: an open label trial. 2019 , 4, 45	1
61	Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. 2016 , 13, e1002160	124
60	Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. 2015 , 10, e0123373	23
59	Atazanavir exposure is effective during pregnancy regardless of tenofovir use. 2015 , 20, 57-64	13
58	Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. 2008 , 69, 652-8	99
57	Prenatal Developmental Toxicity Study of Glycosides-based Standardized Fenugreek Seed Extract in Rats. 2017 , 13, S135-S141	4
56	Comparison of Three Different Concentrations of Levobupivacaine for Epidural Labor Analgesia: Clinical Effect and Pharmacokinetic Profile. 2018 , 12, 60-66	1
55	Use of Antibiotics in Pregnant Patients in the Intensive Care Unit. 2007 , 168-182	1
54	Women and epilepsy. 2009 , 14, 212-20	3
53	Individual (Personalized) Vulnerabilities. 2010 , 145-161	1

52 Clinical Pharmacology and Anticancer Drugs. **2010**, 11-26

51 Arrhythmias in Pregnancy and Postpartum. **2011**, 339-354

50 Specific considerations. **2011**, 35-126

49 Pharmacokinetic Studies in Pregnant Women. **2011**, 195-209

48 Pharmakokinetische Veränderungen in der Schwangerschaft. **2011**, 32,

47 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies. 23-37

46 Médicaments et adaptation néonatale : l'ajustement médicamenteux. **2012**, 196, 717-737

45 Pharmacokinetics in Pregnancy. 53-62

44 Key Concepts in Drug Therapy for Children, Lactating Mothers and Pregnant Women. **2013**, 44, 281-285

43 General Principles and Guidelines. **2014**, 1-9

42 Maternal and Fetal Factors That Influence Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants. **2014**, 33-46

41 Physiological factors that influence drug delivery to the brain. **2015**, 94-110

40 H1N1 with adult respiratory distress syndrome for emergency lower segment cesarean section: A case report. **2016**, 10, 366-7

39 Pharmacokinetics of Systemic Anticancer Therapies During Pregnancy. **2016**, 55-70

38 Non-Front-Fanged Colubroid Snakes. **2017**, 1-41

37 Non-Front-Fanged Colubroid Snakes. **2017**, 1-41

36 Non-Front-Fanged Colubroid Snakes. **2017**, 2453-2492

35 Concentration of Sulfate and Glucuronide Conjugates of Ritodrine in Twin Pregnancy. **2017**, 40, 922-925

34	FARMACOCINÉTICA E MECANISMOS DE TERATOGENICIDADE DOS MEDICAMENTOS NA GESTAÇÃO: UMA REVISÃO DA LITERATURA.. 2017 , 29, 100-107	1
33	Anesthesia for the Parturient with Intracranial and Spinal Surgery. 2018 , 99-116	0
32	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. 4, 45	
31	The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions. 2021 , 17, 1261-1279	0
30	Pharmacokinetics and Pharmacodynamics of Chemotherapy for Leukemia in Pregnancy. 2021 , 77-93	
29	Preconception Counseling for Women with Congenital Heart Disease. 2015 , 31, 500-6	3
28	Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks.. 2022 , 14, 62-74	3
27	Special Considerations in the Management of Women with Epilepsy in Reproductive Years.. 2022 , 12,	1
26	Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network. 2021 ,	0
25	Pharmacokinetics in pregnancy. 2022 , 33-46	0
24	[Impact of pregnancy on drug pharmacokinetics: what implication in clinical practice?]. 2022 ,	
23	Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.. 2022 ,	2
22	Considerations and challenges for sex-aware drug repurposing.. 2022 , 13, 13	1
21	Cytochrome P450 isoforms contribution, plasma protein binding, toxicokinetics of enniatin A in rats and in vivo clearance prediction in humans.. 2022 , 112988	0
20	Strategies for low-molecular-weight heparin management in pregnant women with mechanical prosthetic heart valves: A nationwide survey of Dutch practice. 2022 , 100373	
19	Population pharmacokinetics of doxorubicin: A systematic review.. 2022 ,	0
18	Desmoplastic Small Round Cell Tumor in a Pregnant Woman: A Case Report and Literature Review.. 2021 , 94, 613-622	1
17	Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.. 2022 ,	5

16	The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. 2009 , 14, 443-450	16
15	Pharmacological approaches to prevent vertical transmission of HIV and HBV.	
14	Pain Management in Pregnancy and Lactation. 2022 , 189-218	o
13	Hormones and drug-metabolizing enzymes: From function to regulation. 2022 , 141-159	o
12	Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies. 2022 , 62,	o
11	Reproductive Health after Thoracic Transplantation: An ISHLT Expert Consensus Statement. 2022 ,	o
10	An Overview: Pharmacology During Pregnancy. 2023 , 95-97	o
9	Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy. 2023 , 181, 106349	o
8	Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age?. 2022 ,	o
7	Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. 2022 , 14, 2733	1
6	Human Maternal-Fetal Interface Cellular Models to Assess Antiviral Drug Toxicity during Pregnancy. 2022 , 3, 303-319	o
5	Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study. 2022 , 12, 1281	o
4	The MPRINT Hub Data, Model, Knowledge and Research Coordination Center: Bridging the gap in maternal-pediatric therapeutics research through data integration and pharmacometrics.	o
3	Genetic and physiological factors predisposing to individual selective serotonin reuptake inhibitors exposure during pregnancy and breast feeding. 2023 , 6-14	o
2	Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort. 2023 , 7, 127-139	o
1	Effects of genetic polymorphisms of CYP2J2, CYP2C9, CYP2C19, CYP4F2, CYP4F3 and CYP4A11 enzymes in preeclampsia and gestational hypertension. 2023 , 137, 88-95	o